For decades, the metabolism of cannabinoids has been a subject of intense scrutiny, particularly due to the differential effects observed among users. While numerous environmental and physiological factors have been studied, the genetic underpinnings have remained largely elusive. This study, led by a team including J. Schulte, L. Potzel, and P. Frei among others, provides compelling evidence that variations in the genes encoding for hepatic enzymes CYP2C9 and CYP2C19 markedly modulate the metabolic fate of CBD. These enzymes, belonging to the cytochrome P450 family, are integral to drug metabolism, catalyzing phase I oxidative reactions that transform lipophilic substances into more hydrophilic products suitable for elimination.

The researchers employed a meticulously designed protocol, administering controlled doses of CBD-cannabis to subjects stratified by their CYP2C9 and CYP2C19 genotypes. This allowed a direct comparison of metabolic rates and the detection of distinct metabolic fingerprints linked to each polymorphism. The approach entailed both single-administration and repetitive administration regimens, thereby unveiling not only immediate enzymatic activity but also potential adaptive changes over time. Such an approach adds significant granularity to the understanding of cannabinoid pharmacokinetics, as repeated exposure often induces metabolic enzyme modulation, which influences drug efficacy and toxicity profiles.

One of the key findings was that individuals harboring CYP2C9 *3 allele variants exhibited noticeably reduced metabolic clearance of CBD, leading to elevated plasma concentrations and prolonged exposure. This has far-reaching implications, especially for patients utilizing CBD therapeutically, as higher systemic levels could amplify both beneficial and adverse effects. Conversely, normal-function alleles were associated with standard metabolic rates, underscoring the variability inherent in cannabinoid processing. Similar genotype-dependent metabolic trends were observed with CYP2C19 polymorphisms, although the effect size appeared somewhat less pronounced but still clinically relevant. Together, these discoveries highlight the complex interplay between genetics and cannabinoid metabolism.

Crucially, the study expands beyond single-dose pharmacokinetics, illuminating how repetitive CBD consumption may induce differential enzymatic activity—a phenomenon known as enzyme induction or inhibition—which could either attenuate or exacerbates drug levels depending on genotype. The CYP2C family’s inducible nature suggests that repeated cannabis use could dynamically impact metabolism, potentially complicating therapeutic dosing schemes. For instance, some genotypes may experience cumulative effects or altered metabolic capacity over time, warranting genotype-specific guidelines for long-term CBD administration.

Beyond pharmacological insights, this research carries profound implications for forensic medicine and toxicology. Accurate interpretation of CBD concentrations in biological samples is paramount during legal investigations or workplace drug testing, situations where misinterpretation of metabolite levels could lead to unjust outcomes. Understanding genotype-specific metabolism can refine these assessments, reducing false positives or negatives and enhancing the fairness of forensic conclusions. This study, therefore, bridges the gap between molecular genetics and forensic application, laying the groundwork for more personalized and precise drug monitoring approaches.

Another particularly intriguing aspect discussed is the potential interaction between CBD metabolism and other concomitantly administered pharmaceuticals metabolized by CYP2C9 and CYP2C19 enzymes. Given the polypharmacy common in clinical populations, especially in neurological and psychiatric disorders, the identification of genetic factors influencing CBD metabolism raises awareness about possible drug-drug interactions. For example, drugs that inhibit or induce these enzymes may alter CBD clearance, impacting its therapeutic window. Precision genotyping for CYP variants could become an essential step in mitigating such risks.

The methodology applied in this study involved sophisticated genotyping techniques coupled with quantitative assays using state-of-the-art mass spectrometry. This enabled the precise quantification of CBD and its metabolites over time, allowing for the construction of detailed pharmacokinetic models stratified by genotype. Such technical rigor ensures the reliability and reproducibility of findings, encouraging future studies to adopt similar frameworks to deepen our understanding of cannabinoid metabolism. Furthermore, the controlled study design, eliminating confounding variables such as tobacco or alcohol use, strengthens the causal link between genetic differences and metabolic outcomes.

Importantly, this work also brings to light the broader relevance of metabolic genotype screening in the future of medical cannabis therapies. Personalized medicine, which tailors treatments based on individual genetic profiles, stands to gain significantly from incorporating cytochrome P450 genotyping. By anticipating metabolic responses, clinicians can optimize CBD dosing to achieve maximum efficacy with minimal adverse reactions, marking a paradigm shift away from one-size-fits-all approaches. This could be especially critical in populations with genetic polymorphisms that drastically alter drug processing.

The research team also discusses the dynamics of other minor cannabinoids and their interplay with CBD metabolism, hinting at a complex metabolic network influenced by multiple enzymes and genetic variables. Considering cannabis’ broad phytochemical spectrum, unraveling these interactions will be key to developing comprehensive pharmacogenomic maps. This serves not only the medical community but also regulatory agencies involved in cannabis product standardization and safety evaluations, spotlighting the need for nuanced guidelines that acknowledge interindividual metabolic variability.

Environmental factors such as diet, age, and comorbid conditions undoubtedly modulate enzyme activity and cannabinoid metabolism; however, the clear demonstration of genotype-dependent variability asserts genetics as a foundational determinant. Future research inspired by these findings might explore gene-environment interactions, potentially illuminating how lifestyle factors modulate genetic predispositions in the context of CBD metabolism. Such multifactorial insights would further refine personalized treatment plans and public health strategies.

The implications of this research extend to the development of CBD-based therapeutics targeting complex disorders such as epilepsy, chronic pain, and anxiety. For patients resistant to conventional therapies, understanding metabolic genotype backgrounds could predict response rates and optimize dosing schedules, improving clinical outcomes. Additionally, the findings encourage robust clinical trial designs that stratify subjects by metabolic genotypes, ensuring more accurate interpretations of therapeutic efficacy and safety.

Collaboration across disciplines—molecular genetics, pharmacology, forensic science, and clinical medicine—is highlighted as essential to translate these findings into practice. Integrating genotype data into electronic health records and prescribing systems could revolutionize cannabis therapeutics, pushing the field toward truly customized interventions. This integration promises enhanced patient adherence, reduced side effects, and improved overall healthcare efficiency.

As acceptance and legalization of cannabis products continue to grow worldwide, the importance of understanding the genetic factors influencing cannabinoid metabolism gains urgency. This study paves the way for both clinicians and consumers to appreciate the biological underpinnings of varied responses to CBD, fostering more informed decisions and safer use. It also challenges the cannabis industry to innovate formulations optimized for genetic subpopulations, potentially elevating product efficacy and consumer trust.

In summary, this pivotal research underscores the vital impact of CYP2C9 and CYP2C19 genotypes on CBD metabolism following controlled consumption, revealing crucial insights for personalized medicine, forensic applications, and public health. By elucidating how genetic polymorphisms modulate enzymatic activity and pharmacokinetics, the study heralds a new frontier in cannabinoid science where precision genetic profiling guides safe and effective CBD use. Such advances promise to unlock the full therapeutic potential of cannabis derivatives while mitigating risks associated with metabolic variability.

As the medical and scientific communities continue to grapple with the complexities of cannabis pharmacology, studies like this demonstrate the indispensability of integrating genetics into comprehensive metabolic assessments. The implications reach beyond cannabinoids, offering a model for investigating other phytochemicals and drugs influenced by cytochrome P450 enzymes. Ultimately, this research exemplifies the transformative power of pharmacogenomics in tailoring healthcare to the unique genetic blueprint of each individual.

Subject of Research: Genetics and metabolism of CBD-cannabis influenced by CYP2C9 and CYP2C19 genotypes after controlled consumption.

Article Title: Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.

Article References: Schulte, J., Potzel, L., Frei, P. et al. Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption. Int J Legal Med (2026). https://doi.org/10.1007/s00414-025-03708-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00414-025-03708-7

Traditional monooxygenase cytochrome P450s, although extraordinary in substrate versatility and oxidation capacity, have been hampered by their reliance on expensive nicotinamide cofactors such as NAD(P)H and the inefficient electron transfer mediated via redox partner proteins. These limitations not only inflate the cost but also complicate the operational stability and scalability of such enzymatic systems for industrial applications. Contrastingly, CYP152 family enzymes, designated as P450 peroxygenases, circumvent these barriers by utilizing hydrogen peroxide (H₂O₂) directly as an oxidant. This unique catalytic mechanism renders them exceptionally attractive for green chemistry since H₂O₂ is cheap, readily available, and its reduction byproduct is merely water, thereby aligning the enzymatic process with sustainable and atom-economical principles.

Prof. Li’s research group has meticulously dissected and expanded the catalytic potential of microbial CYP152 peroxygenases through intensive molecular engineering. Their approach includes exploring the enzymatic mechanisms, discovering novel enzyme variants, and strategically modifying the protein architecture to enhance substrate specificity and catalytic efficiency. Previous contributions from this group, published across several respected journals, have laid the groundwork for the latest achievement in asymmetric biotransformations, showcasing the robust nature of these biocatalysts and their adaptability toward structurally diverse substrates.

The centerpiece of this breakthrough is the engineering of the P450_BSβ peroxygenase variants, notably the F46A and F292A mutants. These engineered enzymes demonstrate remarkable proficiency in converting phenylacetic acid derivatives — inexpensive and readily accessible starting materials — into (R)-mandelic acid derivatives with unprecedented enantioselectivity and catalytic turnover. The reported total turnover numbers (TTNs) reach an impressive 11,722, indicative of both high enzymatic stability and efficient substrate conversion, while consistently achieving enantiomeric excess (ee) values above 99% across multiple substrate examples. This level of enantio-purity is critical for the application of these hydroxy acids as chiral building blocks in pharmaceutical synthesis.

The ramifications of this enzymatic platform extend far beyond mere synthetic achievement. (R)-mandelic acid and its derivatives occupy a central position in organic synthesis as chiral resolving agents, precursors to medicinal compounds, and key intermediates in various pharmaceutical manufacturing processes. Historically, the synthetic routes toward these molecules have been fraught with difficulties — limited yields, poor stereocontrol, harsh chemical conditions, and environmental burdens from hazardous reagents. The enzymatic route developed by Li et al. offers a sustainable and atom-economic alternative, circumventing the need for metal catalysts or complex cofactor recycling systems, and operating effectively under ambient conditions.

One of the most compelling demonstrations of this technology’s practicality is its scalability. The researchers successfully executed semi-preparative syntheses of (R)-mandelic acid and (R)-p-fluoromandelic acid with isolated yields exceeding 92%, affirming the method’s potential transition from laboratory curiosity to industrial utility. These results exemplify how biocatalysis can marry green chemistry principles with industrially relevant production metrics, potentially revolutionizing the manufacture of high-value chiral hydroxy acids.

Underpinning the enzymatic performance, the structural insights into the CYP152 active site modifications reveal how subtle amino acid substitutions, such as those at phenylalanine residues 46 and 292, modulate the enzyme’s substrate binding pocket and catalytic geometry. These alterations enhance substrate positioning and reactivity, facilitating efficient hydrogen peroxide activation and selective α-hydroxylation. This precision engineering underscores the power of protein design and directed evolution methodologies in tailoring enzyme functionality toward bespoke synthetic goals.

The environmental implications of deploying CYP152 peroxygenase-based processes are significant. By replacing conventional chemical oxidations, which often rely on expensive and toxic metal catalysts or stoichiometric oxidants generating harmful waste, this biocatalytic system adheres to the principles of green chemistry. It reduces hazardous waste generation, lowers energy consumption due to mild operating conditions, and utilizes a benign oxidant whose decomposition product is innocuous water. Such advantages align with global efforts to minimize the chemical industry’s environmental footprint while enhancing process efficiency.

Looking forward, the success of this enzymatic platform paves the way for expanding the substrate repertoire of CYP152 peroxygenases to other structurally challenging molecules, thereby broadening the scope of sustainable biomanufacturing in pharmaceuticals and fine chemicals. The modular nature of enzyme engineering suggests that further customization could unlock access to a wider array of chiral hydroxylated products, offering unprecedented flexibility in synthetic routes.

This research not only marks a pivotal advance in enzyme catalysis but also exemplifies the broader convergence of biotechnology, synthetic chemistry, and sustainable industrial practices. Prof. Li’s statement emphasizes that this strategy not only enriches the toolbox available for chiral molecule preparation but also contributes significantly to the green production of high-value compounds crucial for medicinal and synthetic chemistry.

The study benefits from substantial support provided by the National Natural Science Foundation of China and the Natural Science Foundation of Shandong Province, reflecting the strategic importance and potential impact of this work on both scientific and industrial sectors.

As the chemical industry seeks to transition toward greener methodologies, innovations like this CYP152 peroxygenase system stand at the forefront, demonstrating that sustainable biocatalysis can meet, and even exceed, the efficacy of traditional synthetic approaches. The integration of such enzymatic tools promises to redefine chiral synthesis paradigms, unlocking new avenues for efficient and environmentally friendly drug development.

Subject of Research: Biocatalytic asymmetric α-hydroxylation of aromatic carboxylic acids using engineered CYP152 peroxygenases.

Article Title: CYP152 Peroxygenases Open a Green Pathway to Chiral Molecules.

News Publication Date: Information not explicitly provided; article DOI indicates 2025.

Web References:
http://dx.doi.org/10.1016/j.scib.2025.10.031

References:
Angew. Chem. Int. Ed. 2025, 2021; Sci. Bull. 2024; Biotechnol. Biofuels 2020, 2019, 2017, 2015, 2014; ChemCatChem 2019; Sci. Rep. 2017

Image Credits: ©Science China Press

Keywords

Life sciences, Health and medicine, Chemistry, Pharmaceuticals

Dengue virus, transmitted primarily by Aedes aegypti, remains a significant challenge to global health, affecting millions annually with potential severe outcomes such as dengue hemorrhagic fever and dengue shock syndrome. Traditional vector control methods, including insecticides and habitat elimination, have struggled to keep pace with expanding mosquito populations and viral spread. Against this backdrop, the report by Merkling, Couderc, Crist, and colleagues provides a molecular glimpse into how natural genetic variation within mosquito populations modulates their capacity to harbor and transmit the virus, essentially influencing epidemic dynamics at the population level.

Central to the team’s discovery is the identification of promoter variants that fine-tune expression of specific cytochrome P450 enzymes. These enzymes, often associated with detoxification of insecticides and metabolic processing of xenobiotics, appear to play a more intricate role in the mosquito’s biology than previously recognized. By influencing gene expression levels via promoter modifications, these genetic variants alter the mosquito’s internal environment, thereby modulating permissiveness to viral replication and systemic spread within the vector.

Employing a combination of genomic sequencing, functional assays, and viral challenge experiments, the researchers systematically mapped the variation in the promoter regions across geographically distinct Aedes aegypti populations. They identified distinct allelic variants correlating with differential expression of cytochrome P450 genes that corresponded meaningfully with varying degrees of dengue virus susceptibility. This approach underscores the importance of integrating population genomics with pathogen biology to unravel complex vector-host interactions that dictate transmission efficiency.

Interestingly, the study demonstrates that promoter variants do not act in isolation but appear to interplay with the mosquito’s immune pathways and metabolic networks. The modulation of cytochrome P450 gene expression influences oxidative stress responses and other biochemical pathways that can either inhibit or promote viral replication within various tissues. This complexity highlights a multifaceted genetic architecture wherein host factors beyond canonical immune genes are pivotal in determining vector competence.

These findings challenge the conventional focus on immune-related genes as primary modulators of arboviral susceptibility, suggesting that metabolic genes and their regulatory elements can be equally influential. Moreover, the promoter variants studied are naturally occurring within wild mosquito populations, meaning that this genetic diversity is a preexisting substrate upon which environmental pressures and viral evolution can act, shaping transmission dynamics in real-world settings.

From an applied perspective, the identification of cytochrome P450 promoter variants as susceptibility loci opens novel possibilities for genetic interventions. Techniques such as gene editing or gene drive mechanisms could target these regulatory regions to engineer mosquito populations with reduced competence for dengue viruses. Such strategies might complement or even supersede existing vector control methods, providing a more sustainable and targeted approach to mitigate dengue transmission.

Furthermore, understanding the interplay between detoxification pathways and viral susceptibility raises important considerations regarding the use of insecticides. Selection pressures imposed by chemical control could inadvertently influence promoter variant frequencies, potentially enhancing or diminishing mosquito susceptibility to the virus. Therefore, this study calls for a nuanced assessment of vector control programs in light of mosquito genetics to avoid unintended consequences that might exacerbate pathogen spread.

The research also delves into the mechanistic underpinnings of how cytochrome P450 enzymes influence viral infection at a cellular level. Experimental data suggest that altered enzyme levels impact cellular redox states, lipid metabolism, and membrane composition, all of which can affect dengue virus entry, replication, and assembly. These biochemical changes create microenvironments either conducive or hostile to viral propagation, providing mechanistic links between genotype and phenotype.

Moreover, the study adopts a multidisciplinary strategy—blending molecular genetics, virology, biochemistry, and ecology—to paint a comprehensive picture of vector-virus interactions. Such integrative approaches are crucial since vector competence is a polygenic trait influenced by environmental factors and gene-environment interactions. The insight that promoter variants can act as genetic switches modulating susceptibility invites reexamination of previous assumptions that primarily focused on coding sequences and immune genes.

The global significance of this work is underscored by the widespread distribution of Aedes aegypti and the increasing burden of dengue globally, exacerbated by climate change, urbanization, and globalization. Identification of genetic factors that govern viral susceptibility provides policymakers and public health professionals with new molecular markers for surveillance and risk assessment, enabling precision targeting of control efforts in regions with high transmission potential.

In the broader context of arbovirus research, these findings may stimulate analogous investigations into other vector species and pathogens, expanding our understanding of vector competence determinants. The notion that promoter variation within metabolic gene families can influence pathogen susceptibility could be a generalizable principle, advancing the field towards more sophisticated models predicting disease emergence and spread.

Finally, this research exemplifies the power of genomics and molecular biology in tackling pressing global health challenges. By elucidating intricate genetic mechanisms underlying mosquito-virus interactions, it paves the way towards innovative, genetics-informed strategies for vector management. As the fight against dengue and related diseases intensifies, such foundational knowledge will be indispensable for developing the next generation of interventions that are both effective and ecologically sound.

Subject of Research: Dengue virus susceptibility mechanisms in Aedes aegypti mosquitoes linked to cytochrome P450 promoter genetic variation.

Article Title: Dengue virus susceptibility in Aedes aegypti linked to natural cytochrome P450 promoter variants.

Article References:
Merkling, S.H., Couderc, E., Crist, A.B. et al. Dengue virus susceptibility in Aedes aegypti linked to natural cytochrome P450 promoter variants. Nat Commun 16, 7468 (2025). https://doi.org/10.1038/s41467-025-62693-y

Image Credits: AI Generated

Traditional experimental methods for assessing CYP450-mediated metabolism, though invaluable, are often constrained by high costs, extensive timelines, and limited scalability. These limitations hamper early-stage drug screening where rapid and accurate predictions are paramount. In response, computational approaches have evolved, moving from simplistic rule-based algorithms to sophisticated machine learning paradigms. Among these, graph-based models—particularly Graph Neural Networks (GNNs), Graph Convolutional Networks (GCNs), and Graph Attention Networks (GATs)—have emerged as powerful instruments. By representing molecules and their interactions as graphs, these networks can harness structural and electronic nuances inherent in chemical and protein architectures, capturing the multifaceted enzyme-ligand interplay essential for metabolic prediction.

Focusing on five pivotal CYP isoforms—CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4—current research exploits graph-based techniques to disentangle their distinct metabolic roles and substrate specificities. These isoforms account for the majority of xenobiotic metabolism, rendering their accurate modeling critical. Graph-based deep learning frameworks analyze molecular graphs to predict not only binding affinities but also the metabolic rates and potential toxicities with enhanced granularity. This method surpasses traditional descriptor-based models by directly encoding atom-level connectivity and bond relationships, leading to more robust and generalizable ADMET predictions.

Incorporating multi-task learning represents a significant leap in model sophistication, allowing simultaneous prediction of various pharmacokinetic parameters across multiple CYP450 isoforms. This approach trains a single model to understand shared and isoform-specific features concurrently, thereby improving predictive power and reducing overfitting risks. Additionally, attention mechanisms embedded within GATs have dramatically enhanced interpretability by selectively focusing on crucial molecular substructures influencing enzyme interactions. Such insights shine a light on biochemical determinants driving metabolism, aiding medicinal chemists in rational drug design and optimization.

Parallel to these advancements, the integration of explainable AI (XAI) techniques addresses a critical bottleneck in deploying machine learning models in pharmacology: transparency. By elucidating model decision pathways, XAI bridges the gap between computational predictions and experimental validation, fostering trust and facilitating hypothesis generation. Researchers can now pinpoint which molecular features most significantly impact CYP450 metabolism, enabling targeted modifications to ameliorate adverse effects or enhance bioavailability.

However, despite these breakthroughs, several challenges persist. Dataset variability, stemming from heterogeneous experimental conditions and limited high-quality metabolic data, poses considerable hurdles to model generalization. Furthermore, extrapolating predictions to novel chemical spaces remains an open problem, as models often struggle with out-of-distribution compounds that defy learned patterns. Addressing these issues demands concerted efforts to curate expansive, standardized datasets and advance transfer learning methodologies capable of adapting to emerging chemical entities.

Scalability also represents a frontier for future research. While current graph-based models deliver impressive accuracy, their computational demands can impede application in high-throughput screening pipelines. Optimizing algorithmic efficiency, leveraging advanced hardware acceleration, and developing lightweight model variants will be essential to translate these tools into routine pharmaceutical workflows. Moreover, real-time experimental validation, integrated with in silico predictions, could establish feedback loops to continuously refine model fidelity and accelerate drug candidate evaluation.

Another promising trajectory lies in deepening our understanding of enzyme-specific interactions at atomic resolutions. Beyond static representations, incorporating dynamic conformational changes and allosteric effects within graph architectures could unravel further layers of metabolic complexity. Such integration necessitates interdisciplinary collaboration, melding computational chemistry, structural biology, and machine learning to engineer comprehensive predictive frameworks.

The confluence of these technological and scientific advances signals a transformative era for ADMET prediction. Graph-based models, empowered by multi-task learning, attention mechanisms, and explainable AI, are redefining the landscape of drug metabolism studies. Their capacity to simulate complex biochemical interactions with aesthetic precision offers hope for reducing late-stage drug attrition, minimizing adverse drug reactions, and ushering in personalized medicine paradigms rooted in metabolic profiling.

In essence, the evolution from traditional assays to sophisticated graph neural architectures not only augments predictive accuracy but also democratizes access to metabolic insights across the pharmaceutical industry. As datasets expand and computational methods mature, such models promise to become indispensable tools that bridge the gap from molecular design to clinical success. This synergy of bioinformatics and enzymology heralds a future where drug development is faster, safer, and more ingenious.

As researchers continue to tackle existing limitations and harness emerging opportunities, the field marches toward a holistic understanding of drug metabolism. By embracing graph-based approaches, the scientific community is poised to unlock new frontiers in pharmacokinetics, ultimately enhancing therapeutic outcomes and safeguarding patient health on a global scale.

Subject of Research: Cytochrome P450 (CYP450) enzyme-mediated metabolism and ADMET prediction using graph-based computational models.

Article Title: Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions

Article References:
Abdelwahab, A.A., Elattar, M.A. & Fawzi, S.A. Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions.
BioMed Eng OnLine 24, 93 (2025). https://doi.org/10.1186/s12938-025-01412-6

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-025-01412-6